Structure

InChI Key OZVBMTJYIDMWIL-AYFBDAFISA-N
Smiles CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
InChI
InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C32H40BrN5O5
Molecular Weight 654.61
AlogP 3.19
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 5.0
Polar Surface Area 118.21
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 43.0
Assay Description Organism Bioactivity Reference
Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT. Homo sapiens 24.0 nM
In vitro affinity for alpha adrenergic receptor by displacement of 3[H]clonidine in calf cerebral cortex Bos taurus 514.0 nM
Alpha-2 adrenergic receptor activity assessed in vitro for displacement of [3H]clonidine from specific binding sites on rat striatal membranes None 514.0 nM
Dopaminergic activity assessed in vitro for displacement of [3H]apomorphine from specific binding sites on rat striatal membranes None 27.9 nM
In vitro affinity for dopamine receptor by displacement of [3H]- apomorphine in rat striatal membranes Rattus norvegicus 27.9 nM
Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170. Homo sapiens 10.0 nM
In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes. None 8.0 nM
In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes. None 17.0 nM
In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes. None 4.0 nM
In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes. None 8.0 nM
Binding affinity towards Dopamine receptor D3 by displacement of [3H](+)-7-OH-DPAT. Homo sapiens 87.0 nM
Compound was tested for the percent prolactin inhibiting activity at the 0.001 mg/kg dose levels Rattus norvegicus 23.9 %
Compound was tested for the percent prolactin inhibiting activity at the 0.01 mg/kg dose levels Rattus norvegicus 60.4 %
Compound was tested for the percent prolactin inhibiting activity at the 0.1 mg/kg dose levels Rattus norvegicus 90.4 %
Binding affinity for human 5-hydroxytryptamine 6 receptor Homo sapiens 50.0 nM
Inhibition of CETP in rabbit serum at 10 uM after 1 hr by fluorescent cholesteryl esters transfer assay Oryctolagus cuniculus 12.3 %
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) None 5.635 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) None 3.22 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) Rattus norvegicus 103.0 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) Rattus norvegicus 47.0 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) None 36.0 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) None 10.0 nM
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) Rattus norvegicus 6.96 nM DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) Rattus norvegicus 2.817 nM
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) Rattus norvegicus 3.547 nM DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) Rattus norvegicus 1.964 nM
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) None 30.0 nM DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) None 15.0 nM
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) None 15.0 nM DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) None 5.533 nM
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) None 35.0 nM DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) None 16.0 nM
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) None 520.0 nM DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) None 76.0 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) None 8.316 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) None 5.292 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) None 532.0 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) None 278.0 nM
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) None 22.0 nM DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) None 10.0 nM
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) None 1.582 nM DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) None 0.527 nM
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 0.596 nM DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) None 0.202 nM
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) Rattus norvegicus 53.0 nM DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) Rattus norvegicus 35.0 nM
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control Mus musculus 55.0 %
Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins Homo sapiens 15.0 nM Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins Homo sapiens 14.79 nM
Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay Homo sapiens 0.5012 nM
Agonist activity at 5HT2A receptor (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay Homo sapiens 1.778 nM
Antiviral activity against DENV2 16681 infected in African green monkey Vero cells after 3 days by focus reduction assay Dengue virus 2 800.0 nM
Antiviral activity against DENV3 00-40 infected in African green monkey Vero cells after 3 days by focus reduction assay Dengue virus 3 800.0 nM
Antiviral activity against DENV4 09-48 infected in African green monkey Vero cells after 3 days by focus reduction assay Dengue virus 4 800.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 10.39 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.31 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.31 %
Inhibition of recombinant human GALNS expressed in Pichia pastoris at 0.001 to 50 uM using 4MUGPS as substrate incubated for 18 hrs by fluorescence assay relative to control Homo sapiens 30.0 %

Related Entries

Cross References

Resources Reference
ChEBI 3181
ChEMBL CHEMBL493
DrugBank DB01200
DrugCentral 403
FDA SRS 3A64E3G5ZO
Human Metabolome Database HMDB0015331
Guide to Pharmacology 35
KEGG C06856
PDB 08Y
PharmGKB PA448671
PubChem 31101
SureChEMBL SCHEMBL25297
ZINC ZINC000053683151